In a nutshell This study investigated the effectiveness of irinotecan (Camptosar) with and without cetuximab (Erbitux) in the treatment of metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that combined treatment improves the outcomes of these patients. Some background Colorectal cancer (CRC) is one of...
Read MoreType(s) of chemotherapy-Single drug-Irinotecan (Campto) Posts on Medivizor
Searching for patients with advanced colorectal cancer to test a new T-cell treatment
In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MorePanitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations
In a nutshell This study looks at the use of panitumumab and irinotecan as a combination treatment in patients with KRAS wild-type (non-mutated) metastatic colorectal cancer which has continued to progress while on standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan, bevacizumab). Some background Cancer cells can have...
Read MoreTowards guidelines to prevent colorectal cancer recurrence
This article presents results of recent studies concerning the interplay between the body's chemistry and behavioral factors that influence colorectal cancer (CRC) recurrence. Recent advances in CRC treatment have produced new and promising biological treatments. However, tumors sometimes have unique features that render many of these therapies...
Read More